These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38612556)

  • 1. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd K; Niziński P; Kasprzak P; Kondracka A; Oniszczuk T; Rusinek A; Oniszczuk A
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?
    Jakubek P; Kalinowski P; Karkucinska-Wieckowska A; Kaikini A; Simões ICM; Potes Y; Kruk B; Grajkowska W; Pinton P; Milkiewicz P; Grąt M; Pronicki M; Lebiedzinska-Arciszewska M; Krawczyk M; Wieckowski MR
    FASEB J; 2024 Feb; 38(3):e23466. PubMed ID: 38318780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
    Min BH; Devi S; Kwon GH; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Park HJ; Eom JA; Jeong MK; Hyun JY; Stalin N; Park TS; Choi J; Lee DY; Han SH; Kim DJ; Suk KT
    Gut Microbes; 2024; 16(1):2307568. PubMed ID: 38299316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Zhao S; Guo Y; Yin X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model.
    Grandini NA; Costa MR; Gregolin CS; Siqueira JS; Vieira TA; Togneri Ferron AJ; Francisqueti-Ferron FV; Romualdo GR; Lúcia Dos Anjos Ferreira A; Aldini G; Corrêa CR; Moreto F
    Mol Cell Endocrinol; 2024 Mar; 582():112138. PubMed ID: 38147954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways.
    Tamilmani P; Sathibabu Uddandrao VV; Chandrasekaran P; Saravanan G; Brahma Naidu P; Sengottuvelu S; Vadivukkarasi S
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102231. PubMed ID: 37865226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
    Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
    Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions.
    Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials-A Narrative Review.
    Ziółkiewicz A; Niziński P; Soja J; Oniszczuk T; Combrzyński M; Kondracka A; Oniszczuk A
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.
    He QJ; Li YF; Zhao LT; Lin CT; Yu CY; Wang D
    World J Gastroenterol; 2024 Feb; 30(7):652-662. PubMed ID: 38515956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease.
    Guariglia M; Saba F; Rosso C; Bugianesi E
    Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease.
    Tejada S; Capó X; Mascaró CM; Monserrat-Mesquida M; Quetglas-Llabrés MM; Pons A; Tur JA; Sureda A
    Curr Pharm Des; 2021; 27(22):2558-2570. PubMed ID: 32303170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.